Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab monotherapy in adolescents with moderate-to-severe atopic dermatitis
NL-OMON46038Phase 3Active, not recruiting
- Sponsor
- TFS HealthScience
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tralokinumab in atopic dermatitis (AD), sponsored by TFS HealthScience. Primary endpoints: Investigator's Global Assessment response at Week 16 and EASI75 at Week 16. Started Jan 2019; status: active, not recruiting.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON46038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46038.